PGXIS

PGXIS is a biotechnology company, founded in 2007. Our goal is to reinvigorate pharmaceutical R&D by enhanced use of genetic information, thereby ensuring that new drugs have a higher probability of successfully completing clinical trials, reaching market, providing effective therapy for patients. We maintain a virtual drug discovery model, led by our unique Taxonomy3® platform, which uses ground breaking mathematical algorithms to assist successful drug discovery & development. Alongside this we continue to offer our fee-for-service portfolio of pharmacogenomic services. Taxonomy3® utilises genetic data from patient populations, and allows us to screen for, and identify gene-gene interactions (epistasis) for specific disease states. Our experience shows that these interactions account for the ‘missing heritability’ seen in genome-wide association studies (GWAS) of complex diseases. This ability allows us to better define potential drug targets which conventional research methodology will struggle to find. Equipped with the proprietary read-out from Taxonomy3®, we believe that we will be well equipped to enter the drug discovery market with innovative molecules that possess a higher probability of successful clinical development. Our intention is to license these molecules to pharmaceutical companies at the appropriate stage of drug development. PGXIS continues to provide fee-for-service genomics expertise to its customers in the following areas: • Identification and prioritisation of drug targets • Prediction of drug-associated adverse events • Prediction of drug efficacy • In vitro knockdown of genes (see http://www.cytopathfinder.com/eng/) • Strategy and implementation-based PGx consultancy Please see our web site (www.pgxis.com) for more information on any of these applications.